Literature DB >> 29866423

The expression of IMP3 in 366 cases with ovarian carcinoma of high grade serous, endometrioid and clear cell subtypes.

Linghui Lu1, Shunni Wang2, Qin Zhu3, Yuqing Qu4, Weiyong Gu5, Yan Ning6, Xiaochen Chen7, Yiqin Wang8.   

Abstract

The clear cell (CCC), high grade serous (HGSC) and endometrioid (EC) ovarian carcinomas share overlapping histological features. The oncogene IMP3 is implicated in CCC with an elusive utility in differential diagnosis. We collected 366 cases with ovarian primary carcinomas to detect IMP3, Napsin-A and HNF-1β by immunochemistry. In 351 cases, the positive expression rate of IMP3 in CCC was significantly higher than that either in EC or HGSC (p < 0.01). The sensitivity of IMP3 in CCC was higher than Napsin-A but lower than HNF-1β (p < 0.01). The specificity of IMP3 in CCC was lower than Napsin-A but higher than HNF-1β (p < 0.01). The composite markers Napsin-A+/IMP3+ and the IMP3+/HNF-1β+/Napsin-A+ offered the highest odds ratio (p < 0.001), the highest specificity, the highest positive predictive value and the highest positive likelihood ratio. The ROC analysis showed that the combination of Napsin-A, HNF-1β and IMP3 offered the biggest AUC compared with either the singular marker performances or the other binary combinations (p < 0.001). In 15 cases of EC mixed with CCC, IMP3 showed a better discrimination value than the other two markers. Consequently, adding IMP3 to the diagnostic panel might provide some help with the pathological diagnosis of ovarian CCC.
Copyright © 2018 The Authors. Published by Elsevier GmbH.. All rights reserved.

Entities:  

Keywords:  HNF-1β; IMP3; Immunocytochemistry; Napsin-A; Ovarian clear cell carcinoma

Mesh:

Substances:

Year:  2018        PMID: 29866423     DOI: 10.1016/j.prp.2018.05.026

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  3 in total

1.  Identification of biomarkers for the diagnosis and targets for therapy in patients with clear cell ovarian cancer: a systematic literature review.

Authors:  Holly Butler; Omar Saulat; Barbara-Ann Guinn
Journal:  Carcinogenesis       Date:  2022-04-25       Impact factor: 4.741

2.  The Aberrant Expression of MicroRNA-125a-5p/IGF2BP3 Axis in Advanced Gastric Cancer and Its Clinical Relevance.

Authors:  Jing Zhang; Fanghui Ding; Dan Jiao; Qiaozhi Li; Hong Ma
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

3.  Overexpression of IGF2BP3 as a Potential Oncogene in Ovarian Clear Cell Carcinoma.

Authors:  Huidi Liu; Zheng Zeng; Mitra Afsharpad; Caiji Lin; Siwen Wang; Hao Yang; Shuhong Liu; Linda E Kelemen; Wenwen Xu; Wenqing Ma; Qian Xiang; Emilio Mastriani; Pengfei Wang; Jiali Wang; Shu-Lin Liu; Randal N Johnston; Martin Köbel
Journal:  Front Oncol       Date:  2020-01-30       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.